By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Miraculins today said that it has successfully completed a two-part ISO certification audit conducted by the BSI Group.

The Winnipeg, Manitoba-based biomarker-based diagnostics firm said that the audit recommended that the firm receive ISO 13485 certification. The company said the certification is a "critical regulatory and business plan milestone" as heads toward commercial launch of its PreVu Non-Invasive Skin Cholesterol test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.